CGT Catapult Report Shows Industry Progress to Commercialization of Therapies

December 4, 2020
BioPharm International Editors

New data from CGT Catapult has demonstrated progression by the industry toward commercialization of therapies and an increase in GMP manufacturing space.

New data from the Cell and Gene Therapy Catapult (CGT Catapult) report has demonstrated progression by the industry toward commercialization of therapies and an increase in good manufacturing practice (GMP) manufacturing space.

The data, which were presented in a Dec. 1, 2020 press release, indicate that the cell and gene therapy industry is maturing at a promising rate, which is reflected by the number of company expansions that have happened over the course of the year. Additionally, commercially-owned spaces are increasing, with 10 companies now delivering their own GMP pipelines. Growth is primarily being seen in the expansion of existing sites rather than an increase in new licensed facilities.

“It is very pleasing to see the support Innovate UK has provided to the Advanced Therapies sector being built on by industry and the CGT Catapult who continue to work together to create economic growth, increase employment, and help bring amazingly innovative medicines to patients,” said Andy Jones, director of Medicines Manufacturing Industrial Strategy Challenge Fund at Innovate UK, in the press release.

“We can see a clear progress of gene and cell therapies towards commercialization and the consequent growth in GMP manufacturing space to support this,” added Matthew Durdy, CEO at CGT Catapult, in the press release. “Today’s data shows how this industry is set to increase even further with more GMP manufacturing space needed to address the demand, and we look forward to continue working with industry to facilitate this.”

The full survey is available from CGT Catapult.

Source: CGT Catapult

Related Content:

News | Industry News | BioBusiness